Friday, October 03, 2025 12:42:53 AM
I was very disappointed to see ENTA trade lower (after the PR)on Monday premarket as I was hoping to raise needed cash. My cost basis was $7.68 / share as of Monday. I have held shares since July 2024.
Anyway throughout Monday I continued to be surprised by the strength in ENTA shares, so I sold throughout the day and by the end of the day all 24K shares were sold @ an average cost of $11.15. Sure I coulda done better, but all that is 20/20 hindsight. In closing, I know I often trade too much. But I have learned there are times when it is best to take what the market gives you… and bank some profits. I banked $83K and paid my bills. I am not a wealthy man.
Given what I see as ENTA’s increased probability of success going forward and the significant drop to $10, I have started to buy back into the stock. The ENTA story has had multiple twists and turns over the last year. Hang on and do your best not to lose money. Thanks for the insights you provide on this message board. Knowledge is power. Good communication is helpful.
Anyway throughout Monday I continued to be surprised by the strength in ENTA shares, so I sold throughout the day and by the end of the day all 24K shares were sold @ an average cost of $11.15. Sure I coulda done better, but all that is 20/20 hindsight. In closing, I know I often trade too much. But I have learned there are times when it is best to take what the market gives you… and bank some profits. I banked $83K and paid my bills. I am not a wealthy man.
Given what I see as ENTA’s increased probability of success going forward and the significant drop to $10, I have started to buy back into the stock. The ENTA story has had multiple twists and turns over the last year. Hang on and do your best not to lose money. Thanks for the insights you provide on this message board. Knowledge is power. Good communication is helpful.
The creation of a thousand forests is in one acorn.
Recent ENTA News
- Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at ESCMID Global 2026 • Business Wire • 04/07/2026 11:00:00 AM
- Enanta Pharmaceuticals to Present Data for its STAT6 Inhibitor Program at IMMUNOLOGY2026TM, the Annual Meeting of the American Association of Immunologists (AAI) • Business Wire • 03/30/2026 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/26/2026 12:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/13/2026 08:20:56 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/13/2026 08:18:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/13/2026 08:17:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/13/2026 08:14:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/12/2026 08:05:29 PM
- Enanta Pharmaceuticals to Present at The Citizens Life Sciences Conference • Business Wire • 03/03/2026 12:00:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/23/2026 05:15:10 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2026 09:33:34 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2026 09:31:44 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2026 09:29:51 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2026 09:28:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2026 09:27:26 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 02/11/2026 09:43:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/11/2026 09:00:44 PM
- Enanta Pharmaceuticals to Present Preclinical Data for EDP-978, its KIT Inhibitor in Development for the Treatment of Type 2 Immune Diseases, at the 2026 AAAAI Annual Meeting • Business Wire • 02/10/2026 12:00:00 PM
- Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2025 • Business Wire • 02/09/2026 09:01:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 01/26/2026 09:10:39 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 01/26/2026 09:05:32 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 01/20/2026 09:42:25 PM
- Enanta Pharmaceuticals Provides Update on its Research and Development Programs and 2026 Outlook • Business Wire • 01/08/2026 12:00:00 PM
